Literature DB >> 16208278

Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction.

Elfride De Baere1, Silvia Copelli, Sandrine Caburet, Paul Laissue, Diane Beysen, Sophie Christin-Maitre, Philippe Bouchard, Reiner Veitia, Marc Fellous.   

Abstract

Recently the molecular basis of the blepharophimosis-ptosis-epicanthus inversus-syndrome (BPES), an autosomal dominant developmental disorder of the eyelids and ovary, was elucidated. This syndromic form of premature ovarian failure (POF) is caused by mutations in the gene encoding the forkhead transcription factor FOXL2. In this manuscript we review the clinical features of BPES, its molecular basis, the structural and functional characteristics of the FOXL2 gene and protein, and known animal models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16208278

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  4 in total

1.  Blepharophimosis Ptosis Epicanthus Inversus Syndrome (BPES) Type 1 in an Indian Family.

Authors:  Abhinav Kumar Gupta; Deepak Chand Gupta; Saqib Ahmad Khan; Syed Mohd Razi
Journal:  J ASEAN Fed Endocr Soc       Date:  2017-05-09

2.  Granulosa cell tumor mutant FOXL2C134W suppresses GDF-9 and activin A-induced follistatin transcription in primary granulosa cells.

Authors:  Kirsten J McTavish; David Nonis; Yvonne D Hoang; Shunichi Shimasaki
Journal:  Mol Cell Endocrinol       Date:  2013-04-06       Impact factor: 4.102

3.  Transcriptional control of human gametogenesis.

Authors:  Fang Fang; Phillip J Iaquinta; Ninuo Xia; Lei Liu; Lei Diao; Renee A Reijo Pera
Journal:  Hum Reprod Update       Date:  2022-05-02       Impact factor: 17.179

4.  Genetic analysis of the forkhead transcriptional factor 2 gene in three Chinese families with blepharophimosis syndrome.

Authors:  Haiou Jiang; Xueshuang Huang; Zhiguang Su; Libing Rao; Sisi Wu; Ting Zhang; Kang Li; Qingli Quan; Kang Zhang
Journal:  Mol Vis       Date:  2013-02-20       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.